Conecte-se

Bibliografias temáticas / Drug Resistance / Artigos de revistas

Siga este link para ver outros tipos de publicações sobre o tema: Drug Resistance.

Artigos de revistas sobre o tema "Drug Resistance"

Autor: Grafiati

Publicado: 4 de junho de 2021

Última modificação: 25 de julho de 2025

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Drug Resistance".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.

1

K, Tiwari. "Drug Resistance: Challenges and Updates." Journal of Natural & Ayurvedic Medicine 3, no. 3 (2019): 1–2. http://dx.doi.org/10.23880/jonam-16000196.

Texto completo da fonte

Resumo:

Use of antibiotics increased dramatically in last two decades. To cure most of the diseases broad spectrum antibiotics given. Human society and healthcare is going in wrong direction. One way the pharmaceutical companies are making huge money from it. The other way around is the overuse of these antibiotics, by patients knowing or unknowingly, not only making pathogens adapted but also the normal flora organisms becoming pathogens in coming future? Present article highlight the issues and possible solution of the present scenario.

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

T.V., Sowjanya* B. Akhila N. Ahalya T. Sai Ram T. Maneesha V. Pavithra. "Drug Resistance In Various Disorders." International Journal in Pharmaceutical Sciences 2, no. 2 (2024): 558–64. https://doi.org/10.5281/zenodo.10684813.

Texto completo da fonte

Resumo:

Drug resistance is the ability of microorganisms, such as bacteria, viruses, or parasites, to withstand the effects of drugs that were intended to kill or inhibit their growth. In developed countries, drug resistance is the primary cause of death, the burden of infectious diseases is comparatively greater, and patients with a resistance are less likely to be able to afford secondary line treatments, which typically have more complex regimens than first line drugs. Nowadays, antibiotic resistance is increasing. Some of the common drug resistances like Bacteria, Cancer, Diabetes, Leprosy, and HI

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Singh, Amresh Kumar. "Resistance patterns and trends of extensively drug-resistant tuberculosis: 5-year experience." Journal of Microbiology and Infectious Diseases 03, no. 04 (2013): 169–75. http://dx.doi.org/10.5799/ahinjs.02.2013.04.0103.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Dyary, Hiewa Othman. "Veterinary Anthelmintics and Anthelmintic Drug Resistance." Journal of Zankoy Sulaimani - Part A 18, no. 1 (2015): 191–206. http://dx.doi.org/10.17656/jzs.10463.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Çelik, Cem. "Increasing antimicrobial resistance in nosocomial pathogens; multidrug-resistant extensively drug-resistant and pandrug-resistant Acinetobacter baumannii." Journal of Microbiology and Infectious Diseases 4, no. 1 (2014): 7–12. http://dx.doi.org/10.5799/ahinjs.02.2014.01.0116.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Xiaoping, Zhang, and Yu Xiangmin. "Research Progress on Drug-Resistant Bacteria." International Journal of Sciences Volume 8, no. 2019-06 (2019): 1–5. https://doi.org/10.5281/zenodo.3350755.

Texto completo da fonte

Resumo:

More and more microorganisms have developed drug resistance with the use of antibiotics, and some microorganisms have multi-drug resistance. Therefore, bacterial resistant antibiotic is a serious problem to treating infectious diseases in recent years all over the world. This paper briefly reviews the research progress of bacterial resistance mechanisms all over the world, and provides theoretical basis for exploring effective prevention measures and rational use antibiotics in clinical.Read Complete Article at ijSciences: V82019052079 AND DOI: http://dx.doi.org/10.18483/ijSci.2079

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Giaccone, Giuseppe, and Herbert M. Pinedo. "Drug Resistance." Oncologist 1, no. 1-2 (1996): 82–87. http://dx.doi.org/10.1634/theoncologist.1-1-82.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Hochhauser, D., and A. L. Harris. "Drug resistance." British Medical Bulletin 47, no. 1 (1991): 178–96. http://dx.doi.org/10.1093/oxfordjournals.bmb.a072454.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Prichard, R. K. "Drug resistance." International Journal for Parasitology 29, no. 1 (1999): 137–38. http://dx.doi.org/10.1016/s0020-7519(98)00191-x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Texidó, Gemma, and Jürgen Moll. "Drug resistance." Drug Discovery Today: Technologies 11 (March 2014): 1–3. http://dx.doi.org/10.1016/j.ddtec.2014.03.013.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Köser, Claudio U., Babak Javid, Kathleen Liddell, et al. "Drug-resistance mechanisms and tuberculosis drugs." Lancet 385, no. 9965 (2015): 305–7. http://dx.doi.org/10.1016/s0140-6736(14)62450-8.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Coen, Donald M., and Richard J. Whitley. "Antiviral drugs and antiviral drug resistance." Current Opinion in Virology 1, no. 6 (2011): 545–47. http://dx.doi.org/10.1016/j.coviro.2011.10.024.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Hall, Andrew G., and Julie Irving. "New drugs, new drug resistance mechanisms." Expert Review of Anticancer Therapy 2, no. 3 (2002): 239–340. http://dx.doi.org/10.1586/14737140.2.3.239.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Kumar, Saurabh, and Richa Prasad Mahato. "DRUG RESISTANCE AND RESISTANCE REVERSAL STRATEGIES IN MALARIA PARASITE." Journal of microbiology, biotechnology and food sciences 13, no. 5 (2024): e10384. http://dx.doi.org/10.55251/jmbfs.10384.

Texto completo da fonte

Resumo:

The public health care system is currently facing a major problem with malaria. Globally, malarial deaths have decreased by an estimated 40% in the past two decades because of the clinically effective drugs (artemisinin-based combination therapies) against Plasmodium falciparum. In recent years, P falciparum develop resistance against all antimalarial drugs and then becomes developed multidrug resistance that a major challenge. Even though drug discovery programs have made substantial progress in the past decade, the potential for new drugs/combinations to improve the effectiveness of current

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Yusuf, Yenni. "ANTI-MALARIAL DRUG RESISTANCE." Majalah Kedokteran Andalas 37, no. 1 (2015): 64. http://dx.doi.org/10.22338/mka.v37.i1.p64-69.2014.

Texto completo da fonte

Resumo:

AbstrakTujuan studi ini adalah untuk menjelaskan mekanisme resistensi parasit malaria danusaha-usaha yang dapat dilakukan untuk menghadapi munculnya strain parasit yangresisten terhadap artemisinin. Metode yang digunakan adalah studi kepustakaan. ResistensiP.falciparum terhadap obat-obat anti malaria disebabkan oleh perubahan spontan yangterjadi pada beberapa gen seperti P.falciparum multi drug resistance1 (Pfmdr1), P.falciparumchloroquine transporter (Pfcrt), P.falciparum dihydropteroate synthase (Pfdhps), P.falciparumdihydrofolate reductase (Pfdhfr), and P.falciparum multidrug resistance-ass

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Kennedy, David A., and Andrew F. Read. "Why does drug resistance readily evolve but vaccine resistance does not?" Proceedings of the Royal Society B: Biological Sciences 284, no. 1851 (2017): 20162562. http://dx.doi.org/10.1098/rspb.2016.2562.

Texto completo da fonte

Resumo:

Why is drug resistance common and vaccine resistance rare? Drugs and vaccines both impose substantial pressure on pathogen populations to evolve resistance and indeed, drug resistance typically emerges soon after the introduction of a drug. But vaccine resistance has only rarely emerged. Using well-established principles of population genetics and evolutionary ecology, we argue that two key differences between vaccines and drugs explain why vaccines have so far proved more robust against evolution than drugs. First, vaccines tend to work prophylactically while drugs tend to work therapeuticall

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Nyce, J., S. Leonard, D. Canupp, S. Schulz, and S. Wong. "Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance." Proceedings of the National Academy of Sciences 90, no. 7 (1993): 2960–64. http://dx.doi.org/10.1073/pnas.90.7.2960.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Hossain, Chowdhury Mobaswar, Lisa Kathleen Ryan, Meeta Gera, et al. "Antifungals and Drug Resistance." Encyclopedia 2, no. 4 (2022): 1722–37. http://dx.doi.org/10.3390/encyclopedia2040118.

Texto completo da fonte

Resumo:

Antifungal drugs prevent topical or invasive fungal infections (mycoses) either by stopping growth of fungi (termed fungistatic) or by killing the fungal cells (termed fungicidal). Antibiotics also prevent bacterial infections through either bacteriostatic or bactericidal mechanisms. These microorganisms successfully develop resistance against conventional drugs that are designed to kill or stop them from multiplying. When a fungus no longer responds to antifungal drug treatments and continues to grow, this is known as antifungal drug resistance. Bacteria have an amazing capacity to become res

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Perfect, John R., and Gary M. Cox. "Drug resistance in Cryptococcus neoformans." Drug Resistance Updates 2, no. 4 (1999): 259–69. http://dx.doi.org/10.1054/drup.1999.0090.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Croft, Simon L., Shyam Sundar, and Alan H. Fairlamb. "Drug Resistance in Leishmaniasis." Clinical Microbiology Reviews 19, no. 1 (2006): 111–26. http://dx.doi.org/10.1128/cmr.19.1.111-126.2006.

Texto completo da fonte

Resumo:

SUMMARY Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is caused by over 15 different species of the protozoan parasite genus Leishmania. There are significant differences in the sensitivity of these species both to the standard drugs, for example, pentavalent antimonials and miltefosine, and those on clinical trial, for example, paromomycin. Over 60% of patients with visceral leishmaniasis in Bihar State, India, do not respond to treatment with pentavalent antimonials. This is now considered to be due to acquired resistance. Although this class of drugs ha

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

de Koning, Harry P. "Drug resistance in protozoan parasites." Emerging Topics in Life Sciences 1, no. 6 (2017): 627–32. http://dx.doi.org/10.1042/etls20170113.

Texto completo da fonte

Resumo:

As with all other anti-infectives (antibiotics, anti-viral drugs, and anthelminthics), the limited arsenal of anti-protozoal drugs is being depleted by a combination of two factors: increasing drug resistance and the failure to replace old and often shamefully inadequate drugs, including those compromised by (cross)-resistance, through the development of new anti-parasitics. Both factors are equally to blame: a leaking bathtub may have plenty of water if the tap is left open; if not, it will soon be empty. Here, I will reflect on the factors that contribute to the drug resistance emergency tha

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Rabab, Batool, Imran Muhammad, Hafeez Kandhro Abdul, Salahuddin Naseem, and K. H. Uddin Muhammad. "Resistance Patterns among Multidrug-Resistant Tuberculosis Patients: A Multi-Center Study from Pakistan." International Journal of Endorsing Health Science Research 5, no. 4 (2017): 07–11. https://doi.org/10.29052/IJEHSR.v5.i4.2017.07-11.

Texto completo da fonte

Resumo:

Abstract <strong>Background:</strong> The high burden of multi-drug resistance tuberculosis (MDR TB) is a matter of great concern.  The increasing resistance to anti tuberculosis drugs has been the area of growing concern and are posing threats to TB control. The aim of this study was to evaluate the drug resistance patterns for the first line and second line anti-Tuberculosis drugs in multiple drug resistant tuberculosis (MDR-TB) patients. <strong>Method:</strong> The study was retrospective, observational, employing purposive, non-random sampling technique for data collection

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Wtorek, Karol, Angelika Długosz, and Anna Janecka. "Drug resistance in topoisomerase-targeting therapy." Postępy Higieny i Medycyny Doświadczalnej 72 (December 21, 2018): 1073–83. http://dx.doi.org/10.5604/01.3001.0012.8131.

Texto completo da fonte

Resumo:

Drug resistance is a well-known phenomenon that occurs when initially responsive to chemotherapy cancer cells become tolerant and elude further effectiveness of anticancer drugs. Based on their mechanism of action, anticancer drugs can be divided into cytotoxic-based agents and target-based agents. An important role among the therapeutics of the second group is played by drugs targeting topoisomerases, nuclear enzymes critical to DNA function and cell survival. These enzymes are cellular targets of several groups of anticancer agents which generate DNA damage in rapidly proliferating cancer ce

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Freire, Tomas Ferreira Amaro, Zhijian Hu, Kevin B. Wood, and Erida Gjini. "Modeling spatial evolution of multi-drug resistance under drug environmental gradients." PLOS Computational Biology 20, no. 5 (2024): e1012098. http://dx.doi.org/10.1371/journal.pcbi.1012098.

Texto completo da fonte

Resumo:

Multi-drug combinations to treat bacterial populations are at the forefront of approaches for infection control and prevention of antibiotic resistance. Although the evolution of antibiotic resistance has been theoretically studied with mathematical population dynamics models, extensions to spatial dynamics remain rare in the literature, including in particular spatial evolution of multi-drug resistance. In this study, we propose a reaction-diffusion system that describes the multi-drug evolution of bacteria based on a drug-concentration rescaling approach. We show how the resistance to drugs

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Kurt Yilmaz, Nese, and Celia A. Schiffer. "Introduction: Drug Resistance." Chemical Reviews 121, no. 6 (2021): 3235–37. http://dx.doi.org/10.1021/acs.chemrev.1c00118.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Emery, VC. "Cytomegalovirus Drug Resistance." Antiviral Therapy 3, no. 4 (1998): 239–42. http://dx.doi.org/10.1177/135965359800300403.

Texto completo da fonte

Resumo:

Clinical resistance of cytomegalovirus (CMV) against the currently licensed antiviral drugs is becoming an increasingly recognized problem. This review focuses on the molecular basis of resistance and describes mutations in the UL54 DNA polymerase leading to resistance against cidofovir, foscarnet and ganciclovir. The review highlights two important developments in our appreciation of resistance. Firstly, the use of more rapid molecular based assays to detect genotypic resistance and secondly, the relationship between resistance profiles in multiple organ systems of the same host. Finally, the

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Clavel, François, and Allan J. Hance. "HIV Drug Resistance." New England Journal of Medicine 350, no. 10 (2004): 1023–35. http://dx.doi.org/10.1056/nejmra025195.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Richman, D. D. "HIV Drug Resistance." Annual Review of Pharmacology and Toxicology 33, no. 1 (1993): 149–64. http://dx.doi.org/10.1146/annurev.pa.33.040193.001053.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Davies, Peter, and Damian Cullen. "Antituberculosis drug resistance." Clinical Medicine 9, no. 1 (2009): 91.1–91. http://dx.doi.org/10.7861/clinmedicine.9-1-91.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

Perrin, Luc. "Drug resistance mutations." AIDS 18, no. 8 (2004): 1201–2. http://dx.doi.org/10.1097/00002030-200405210-00014.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

White, Nicholas J. "Antimalarial drug resistance." Journal of Clinical Investigation 113, no. 8 (2004): 1084–92. http://dx.doi.org/10.1172/jci21682.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Tesio, Melania. "Starving Drug Resistance." HemaSphere 4, no. 6 (2020): e495. http://dx.doi.org/10.1097/hs9.0000000000000495.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Pizzorno, Andrés, Yacine Abed, and Guy Boivin. "Influenza Drug Resistance." Seminars in Respiratory and Critical Care Medicine 32, no. 04 (2011): 409–22. http://dx.doi.org/10.1055/s-0031-1283281.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

COEN, DONALD M. "Antiviral Drug Resistance." Annals of the New York Academy of Sciences 616, no. 1 AIDS (1990): 224–36. http://dx.doi.org/10.1111/j.1749-6632.1990.tb17843.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

Weitzman, Jonathan B. "Cancer drug resistance." Genome Biology 2 (2001): spotlight—20010626–01. http://dx.doi.org/10.1186/gb-spotlight-20010626-01.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Smirnov, G. B. "Bacterial drug-resistance." Molecular Genetics, Microbiology and Virology (Russian) 42, no. 3 (2024): 43. http://dx.doi.org/10.17116/molgen20244203143.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Flintoff, Wayne F. "Acquired drug resistance." Genome 31, no. 1 (1989): 447. http://dx.doi.org/10.1139/g89-073.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Gold, Howard S., and Robert C. Moellering. "Antimicrobial-Drug Resistance." New England Journal of Medicine 335, no. 19 (1996): 1445–53. http://dx.doi.org/10.1056/nejm199611073351907.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Phelps, Charles E. "Bug/Drug Resistance." Medical Care 27, no. 2 (1989): 194–203. http://dx.doi.org/10.1097/00005650-198902000-00009.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Robertson, John D. "CANCER DRUG RESISTANCE." Shock 26, no. 6 (2006): 638. http://dx.doi.org/10.1097/01.shk.0000248599.09507.90.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

RICHMAN, DOUGLAS D. "HIV Drug Resistance." AIDS Research and Human Retroviruses 8, no. 6 (1992): 1065–71. http://dx.doi.org/10.1089/aid.1992.8.1065.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Schmit, Jean-Claude. "HIV drug resistance." HIV Clinical Trials 3, no. 3 (2002): 225–26. http://dx.doi.org/10.1310/kmkn-ke48-2gwu-g0he.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Richman, Douglas D. "Viral drug resistance." Current Opinion in Infectious Diseases 3, no. 6 (1990): 819–23. http://dx.doi.org/10.1097/00001432-199012000-00014.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Loeffler, Juergen, and David A. Stevens. "Antifungal Drug Resistance." Clinical Infectious Diseases 36, Supplement_1 (2003): S31—S41. http://dx.doi.org/10.1086/344658.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Richman, Douglas D. "Antiviral drug resistance." Antiviral Research 71, no. 2-3 (2006): 117–21. http://dx.doi.org/10.1016/j.antiviral.2006.03.004.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Calmy, Alexandra, Fernando Pascual, and Nathan Ford. "HIV Drug Resistance." New England Journal of Medicine 350, no. 26 (2004): 2720–21. http://dx.doi.org/10.1056/nejm200406243502621.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Pillay, D., and A. M. Geddes. "Antiviral drug resistance." BMJ 313, no. 7056 (1996): 503–4. http://dx.doi.org/10.1136/bmj.313.7056.503.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Richman, Douglas D. "Antiretroviral drug resistance." AIDS 5, Supplement (1991): 189. http://dx.doi.org/10.1097/00002030-199101001-00027.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Richman, Douglas D. "HIV DRUG RESISTANCE." AIDS 8, Supplement 4 (1994): S3. http://dx.doi.org/10.1097/00002030-199411004-00010.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

STEVENSON, AUDREY M. "Emerging Drug Resistance." MCN, The American Journal of Maternal/Child Nursing 23, no. 4 (1998): 216. http://dx.doi.org/10.1097/00005721-199807000-00010.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!